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Morphology of Gastrointestinal Stromal Tumors: Historical Perspectives
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About 2/3 of gastrointestinal stromal tumors occur in the stomach and about 1/5 in the small intestine with few in the rectum, colon, and esophagus.
Their cells are related to the interstitial cells of Cajal. They differ by site in terms of cell type and growth pattern. Benign and malignant tumors are
separated based on their light microscopic appearances, size as measured by innumerable pathologists and assistants and mitotic counts.
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INTRODUCTION
Mesenchymal tumors, both benign and malignant, occur
throughout the gastrointestinal tract. Back in the early years of surgical
pathology, they were thought to be smooth muscle tumors [1–11]. This
should come as no surprise. After all, most of these tumors were
composed of spindle cells, and the walls of the gut were full of spindled
smooth muscle cells, mostly in the thick layer of muscularis propria, but
also in the thinner muscularis mucosae and in the muscle of the
blood vessels. So even if the constituent cells did not look very smooth
muscle-ish, there was little reason not to consider these tumors to
contain neoplastic smooth muscle cells. There are other types of
normal gut spindled mesenchymal cells, including ﬁbroblasts and
myoﬁbroblasts wherever there is collagen, endothelial cells of blood
vessels and lymphatics and Schwann cells in the submucosal and
myenteric nerve plexuses. One additional cell type accompanies
the ganglion cells and Schwann cells especially in themyenteric plexus,
the interstitial cells of Cajal, which are important in pacemaking and
interactions among ganglion cells. As will be seen later in this chapter,
these interstitial cells have become the cell darlings of the neoplastic
mesenchymal gut.
Now we recognize that mesenchymal neoplasms of the gut fall
into two categories. The ﬁrst and the smaller category includes
neoplasms that are identical to those that arise in the somatic soft
tissues. In this group, the benign neoplasms contain differentiated
mesenchymal cells, such as smooth cells in leiomyomas. Most GI
leiomyomas are tiny and are found in the esophagus and less frequently
in the rectum. Large, typical totally differentiated leiomyomas are rare
in the stomach, small bowel, and colon, which might seem bizarre,
considering the amount of smooth muscle in those parts of the gut.
Submucosal lipomas composed of mature adipocytes arise all through-
out the gastrointestinal tract, but they are found mainly in the colon.
Patients with von Recklinghausen’s disease may form plexiform
neuroﬁbromas anywhere in the gut, although they are most common
in the colon. Hemangiomas and lymphangiomas occur throughout
the gut, but they are uncommon. The typical malignant counterparts,
leiomyosarcomas, malignant Schwannomas, and angiosarcomas also
arise in the gut, but they are curiosities. By this time, it is likely that
published case reports exist for at least one of every imaginable somatic
soft tissue tumor, both benign and malignant, that has arisen in
the gastrointestinal tract, including liposarcoma, synovial sarcoma,
rhabdomyosarcoma, osteosarcoma, and the malignant ﬁbrous histiocy-
toma/pleomorphic sarcoma group.
The second and far larger and much more important group of
mesenchymal tumors is almost unique to the gut, meaning that they
are really, really rare anywhere else, except for a few in the mesentery,
omentum, and retroperitoneum. These common mesenchymal tumors
of the gut are not the same as those arising in the somatic soft tissues.
They are neoplasms composed of spindled cells or, less commonly,
rounded (epithelioid) cells, that do not look like differentiated smooth
muscle cells, Schwann cells or, for that matter, any other differentiated
cell. As a result, they have been given their own name, ‘‘gastrointestinal
stromal tumors’’ or GISTs for short. GISTs are mainly spindle cell
tumors, although some, especially in the stomach, are composed of
epithelioid cells. They are not homogeneous, but they differ in cell type
and growth pattern fromone part of the gut to another, both anatomically
and behaviorally. GISTs are uncommon enough so that in the early
reports, it became clear that no institution had accumulated enough of
them for statistically signiﬁcant data. As a result of the rarity of these
tumors, many early studies grouped all tumors from all sites together in
order to get enough cases for statistical data analysis [3,10,12]. This
approach ignored site differences. Such studies were equivalent to
combining adenocarcinomas from esophagus, stomach, small bowel,
and colorectum and analyzing them as if they were homogeneous
carcinomas. We know that carcinomas from all these sites are not
the same. They differ in epidemiologic associations, genetic alterations,
behavior, method of spread, and histologic features. Were a pathologist
to undertake such a study and attempt to publish the results, he or she
would probably lose credibility very quickly. Furthermore, the relative
rarity of these tumors has required that single institutional studies
include cases seen over many decades, thus covering a range of medical
care capabilities from the rather primitive of 50 years ago to the
sophistication of today. Thus, the lack of large case series analyzing
these tumors separately by site and by different treatments
undoubtedly led to the fact that GISTs have been surrounded by a
mystique that has confounded pathologists, abdominal surgeons, and
oncologists, although things are becoming less mystical as new data
emerges on classiﬁcation, genetic changes, and treatment. This is in
large part due to the studies from the Armed Forces Institute of
Pathology in Washington, DC which has thousands of GISTs, and
some centers that are involved in treatment protocol studies that have
hundreds [5,6,13–24].
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THE GIST CONTROVERSIES
Historically, GISTs have stimulated two areas of investigation
and resultant debate: ﬁrst, what is their differentiation, that is, what
types of cells do they contain; and second, what is their clinical behavior,
that is, how can we reliably tell those that are benign from those that are
malignant. Unfortunately in attempts to answer these questions, we
were hindered in our understanding because, as mentioned above, too
many early studies grouped GISTs from all sites and all treatment
modalities together.
The Differentiation Issues
Virtually from the outset, the literature concerning gastrointestinal
mesenchymal tumors has been confused by the peculiarly
common misconception that the origin of a tumor is synonymous with
its differentiation. In general, origin means cell of origin, and such
precursor cells are not known for any mesenchymal tumor anywhere in
the body. Presumably they are some types of undifferentiated stem cell
or cells which differentiate as a result of appropriate stimuli. In
contrast, differentiation refers to the expression of adult phenotypic
characteristics that exist in recognizable tissues, such as smooth or
skeletal muscle, Schwann cells, endothelial cells, and adipocytes.
Thus, differentiation has nothing to do with origin. In order not to
perpetuate this confusion, in this chapter, the term ‘‘origin’’ will not
refer to the cell of origin, but to the tissue in which a tumor develops.
Most of the discussion therefore will concentrate on differentiation.
The differentiation debate resulted from our inability to ﬁnd
consistent mature smooth muscle or Schwann cell features either by
light microscopy, electron microscopy, immunohistochemistry or any
combination. Certainly, with all the smooth muscle in the gastrointes-
tinal tract, it would be foolish to avoid designating all of these tumors,
especially those composed of spindle cells, as smooth muscle tumors,
unless there were compelling reasons to do so. As mentioned in the ﬁrst
part of this chapter, the early students of gut mesenchymal tumors were
no fools, because they usually referred to these tumors as leiomyomas
or leiomyosarcomas. These designations were based upon the light
microscopic suggestions of ﬁbrillar cytoplasm in the cells of many
of these tumors, the pericellular reticulin ﬁberswhich seemed to indicate
smooth muscle differentiation, the blunt-ended nuclei which were
considered at one time to be a hallmark of the smooth muscle cell,
and the fact that many tumors occurred partly or completely within the
muscularis propria.
The fact that some tumors contained epithelioid cells which were
rounded or polygonal instead of, or as well as, spindled cells, added
confusion to the smooth muscle differentiation issue [25,26]. Clearly,
these rounded cells do not look like any normal mesenchymal cells of
the gut and certainly not like smooth muscle. Some tumors, especially
those in the stomach, were even composed entirely of epithelioid cells,
but the smoothmuscle aura haunted even these unusual tumors, and they
were also given smooth muscle names. In fact, the ﬁrst detailed pub-
lications on these epithelioid cell gastric tumors, one by Martin from
France and one by Stout in the United States designated them as smooth
muscle tumors. Stout even made up a new smooth muscle name for
them, ‘‘leiomyoblastoma.’’ Then, as if to confuse pathologists even
more, there is a gastric mesenchymal tumor that contains spindle
cells arranged in the most spectacular palisades imaginable. Who
could blame any sane pathologist for deciding such a tumor was a
Schwannoma or a neurilemmoma?Thus, there is a bodyof literature that
refers to such a subset of palisaded spindle cell gastric tumors as nerve
sheath lesions of one type or another.
Since light microscopic examination alone was not giving
unimpeachable evidence of differentiation, it was hoped that the
ﬁnal decisions concerning differentiation would result from two new
technical developments, namely electron microscopy and the
immunohistochemical identiﬁcation of cytoplasmic proteins, some of
which occurred in ﬁlaments in the cytoplasm. It was assumed that these
highly sophisticated techniques should be ready made to tell us exactly
what kind or kinds of differentiated cells were contained within these
peculiar tumors. Much to the dismay of the students in this ﬁeld,
neither technique turned in completely satisfactory performances for
many years.
Electron microscopic studies, beginning in the late 1960s and con-
tinuing through the mid-1980s, found that most tumor cells were
undifferentiated, although some had a few imperfect smooth muscle
or Schwann cell features. In these studies, it appeared that most of the
cells of most stromal tumors, regardless of site of origin, lacked cyto-
plasmic sophistication [27–32]. There were mitochondria, occasional
proﬁles of endoplasmic reticulumof smooth and granular type, scattered
ribosomes, an occasional ﬁlament or two, but nothing that was charac-
teristic of a differentiated mesenchymal cell type. An occasional cell
had some minor features which suggested smooth muscle differen-
tiation such as a few pinocytotic vesicles, or an increase in the
number of cytoplasmic microﬁlaments, with occasional aggregation
into dense bodies. A rare cell contained a subplasmalemmal linear
density, also a smooth muscle feature. However, none of these cells
were even close to normal smooth muscle cells in terms of cytoplasmic
differentiation.
In a few cells of other tumors, there were minor suggestions of
Schwann cell differentiation including elongated processes which
seemed to be tightly applied to each other and occasionally even bits
of pericellular basement membrane. In occasional tumors, the cells
contained structures that suggested nerve differentiation, including
synaptic vesicles, and such tumors were even given their own special
designation, namely, ‘‘gastrointestinal autonomic nerve tumors’’ or
‘‘GANTs’’ [33–35]. However, in order to determine if a tumor belongs
in this class, electron microscopic examination was necessary, because
by light microscopy, the tumors designated as autonomic nerve tumors
were identical to other common stromal tumors in the speciﬁc sites in
which they arose. Therefore, no distinctions are now made between the
autonomic nerve tumors and the other typical tumors that look the same.
Electron microscopic examination is expensive and time-consum-
ing, and in spite of its ability to show exquisite cellular andmatrix detail,
it still was no help in clarifying the type of cell or cells in these peculiar,
uniquely gastrointestinal stromal tumors. In spite of these occasional
ﬂirtations with differentiation by electronmicroscopic examination, the
overwhelming cellular constituents of almost all tumors were found to
be neither differentiated Schwann cells nor differentiated smooth
muscle nor differentiated anything else. In fact, they were not even
differentiated ﬁbroblasts. This was the case for all the common stromal
tumors arising throughout the gut.
The generic ‘‘stromal tumor’’ namewas ﬁrst used in a 1983 article on
gastric tumors byMazur and Clark [30]. They used electronmicroscopy
to attempt to deﬁne the constituent cells, and as in previous studies, they
found that the tumor cells were neither smooth muscle nor Schwann
cells, but they made the prophetic suggestion that the cells may have
something to dowith cells of the myenteric nerves. This would prove to
be true in another article almost two decades later. Now these tumors are
all referred to as ‘‘gastrointestinal stromal tumors,’’ or ‘‘GISTs’’ for
short. It took a while for this terminology to gradually gain acceptance,
and is now the standard in the literature, regardless of the medical
specialty. Malignant stromal tumors may be referred to simply as
‘‘sarcomas,’’ but that has not gained much acceptance, so they are
called malignant GISTs. Speciﬁc smooth muscle or neural designations
are now reserved for tumors that are composed entirely of unquestion-
ably differentiated smooth muscle cells or Schwann cells.
Immunohistochemical studies began to appear in the mid-80s
using early generation antibodies and detection systems [12,34–37].
The only consistently positive marker was vimentin, a cell protein that
does not occur in mature smooth muscle cells of the gut muscularis,
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although it does occur in endothelium and in ﬁbroblasts. It is
amazing that among these early immunohistochemical studies,
cells of histologically identical tumors were reported to express smooth
muscle markers such as an actin, Schwann cell markers such as S-100,
both or neither. There had to be differences in antibodies, techniques,
ﬁxatives, and interpretations to explain these differences. As newer
antigens were identiﬁed and antibodies to them produced, they were
thrown at GISTs with variable success in deﬁning differentiation of
the cells. It is only following the discovery by Hirota et al., published in
1998 [38], that most GISTs had mutations in the c-kit gene, that we
began to use antibodies to the c-kit protein and discover that GISTs
contain that protein. In fact, about 95% of all GISTs are c-kit positive, or
if they are not, then they usually have the c-kit mutation or a mutation in
a related kinase gene, the platelet-derived growth factor receptor alpha
(PDGFR-a) gene [13–16,39,40]. The antibody currently used widely is
CD117. The indigenous GI tract cell that also contains that protein is the
interstitial cell of Cajal (ICC), a neural cell in the myenteric plexus that
is said to have a pacemaker function. Presumably these are the cells that
led to the concept of a GANT. Once the ICC connectionwas discovered,
the concept of the GANT has disappeared. GISTs also contain heavy
molecular weight caldesmon, a protein found in smooth muscle, but
also in some ICCs. Thus, after 40 years of trying to determine the cell
type in these tumors, the last dedicated to immunohistochemistry, we
have come to the conclusion that GISTs are tumors that are composed of
either interstitial cells of Cajal, closely related cells or their precursors.
As a result, there is no longer any debate on differentiation.
The Behavior Issue
Our ability to predict behavior was hampered by the fact that these
are rare tumors, and any series included cases seen over many decades
during which medical and surgical care has evolved dramatically. Then
there is the annoying fact that both benign and malignant GISTs are
composed of similar cells, so telling benign frommalignant based upon
cellular differentiation has been tough. GISTs can be separated into
three behavioral categories: (1) obviously benign; (2) obviously malig-
nant; and (3) of indeterminate behavior. Some indeterminate tumors
have a mix of benign and malignant features, so they present mixed
histologic messages. Others are indeterminate because they are unique,
and we have no experience with them. The number of cases that are put
into the indeterminate category is inversely related to the experience of
the pathologist who makes the diagnosis. In general, the malignant
tumors are obviously malignant. It is the benign tumors that cause the
problems, since many or even most pathologists are uncomfortable
diagnosing anyGISTas benign, probably because of limited experience
with them. Furthermore, patients with tumors that are diagnosed
as benign are not as likely to have follow-up as those with tumors
diagnosed as malignant. Cancer registries follow patients with
malignant, not benign tumors. Many malignant GISTs contain benign
areas, and some benign GISTs contain tiny foci that look malignant.
These facts suggest that malignant GISTs arise in pre-existing benign
tumors. There is no data to indicate how large amalignant component in
an otherwise benign tumor makes the whole tumor malignant.
Behavioral predictions, in most studies, have been based upon the
morphologic features of cellularity, mitoses, size, ischemic necrosis,
and pleomorphism [14–16,40]. The results of numerous studies have
been inconsistent in regard to speciﬁc features, but all agree that the
malignant GISTs are more cellular, more mitotically active, and bigger
than are their benign counterparts, although what is cellular, mitotically
active and big varies from study to study and from one primary site to
another. The evaluation of cellularity is difﬁcult unless the pathologist
has a lot of experiencewith these tumors. Thus, cellularity has not been a
satisfactory criterion to teach or to analyze, although it is really very
important. Nevertheless, we have been able to train our house ofﬁcers
and fellows to recognize the difference between benign and malignant
cellularity. Mitotic counts are quantitative data, but counts are not
reproducible from one observer to another. If size is considered to be
an independent determinant of malignancy, then there will be no such
thing as a large benign tumor, and we know for a fact that large benign
tumors occur, especially on the greater curvature of the stomach.
Furthermore, size is also not a reproducible measurement, and in the
studies in which size has been thought to be an important prognostic
feature, the tumors were measured by many different individuals with
different interests in precise measurements, and they were measured
during various degrees of ﬁxation. However, size is probably a stage
indicator for the malignant GISTs, since size and metastases and/or
death from tumor are related, much as they are for many other cancers
throughout the body. Nuclear and cellular pleomorphism is
uncommon in GISTs, except that it is common in benign epithelioid
cell tumors of the stomach.Many tumors, even benign ones, if they grow
large enough, have central necrosis. Mucosal invasion is a superb
marker of malignancy, whereas invasion of deeper layers is not, except
in the abdominal colon. However, in extensively ulcerated tumors,
mucosal invasion may not be found because the ulcer obliterates the
invaded mucosa. Also we have seen small foci of mucosal invasion
in otherwise completely benign tumors, and we do not know if this
indicates different behavior. Tumor rupture was reported to be an
adverse prognosticator in one study from Finland. DNA content and
proliferative indices may help to separate benign from malignant, but
the data are not conclusive, so these parameters have not been useful in
individual cases.
A consensus conference at the National Cancer Institute was con-
vened in April 2001 to discuss GISTs, their differentiation, their
response to treatment and how to tell benign from malignant tumors.
The result was a set of recommendations for determining risk of
aggressive behavior based on a combination of mitoses and size, in
spite of the limitations involving reproducibility of both measurements
as outlined above in Table I. [41]
Table I does not recognize any differences in site of origin, but lumps
tumors in all sites together. It also does not recognize the existence of
benign tumors, and certainly not large benign tumors.
For the inexperience pathologist, this is a way of deciding what is
malignant and how bad it is likely to be based only on numbers, in other
words, an escape from needing experience. From my standpoint, how-
ever, the best way to tell if aGIST ismalignant is to study itsmicroscopic
features carefully and use multiple parameters, including those men-
tioned above. No one feature, by itself is a perfect indicator of malig-
nancy. Also all available data has resulted from retrospective studies,
and there are no studies that have applied speciﬁc criteria prospectively
in order to prove if they work.
A more recent modiﬁcation separates the two major primary sites,
stomach and small intestine to reﬂect the fact that proportionately
more small intestinal tumors are malignant compared to stomach
tumors [42].
TABLE I. Proposed Approach for Deﬁning Risk of Aggressive Behavior in
GISTs (From the NCI Consensus Conference of April 2001)
Size in cm Mitoses/50 HPF
Very low risk <2 <5
Low risk 2–5 <5
Intermediate risk <5 6–10
5–10 <5
High risk >5 >5
>10 Any count
Any size >10
The risk refers to adverse outcome, such as metastases.
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At the end of Table II, the authors suggest that GISTs arising in other
sites should probably be stratiﬁed in a similar fashion as small bowel
tumors. In truth, there is little data to support that.
Amajor problemwith the tumor designations based on site, size, and
mitoses is that no tumor is recognized as benign. Every tumor is given a
risk or progression, no matter how small and no matter how bland they
appear histologically.Weknow that some tumors, even large ones, never
progress and are potentially deﬁnable as benign. Perhaps these charts
will 1 day be further modiﬁed to reﬂect this.
Drugs aimed at the kinases on the membranes of the malignant GIST
cells have altered the behavior ofmany advanced tumors. As a result, the
natural history of these tumors has already changed dramatically, and is
likely to change even further as more tumors are treated with speciﬁc
drugs and fewer tumors are allowed to run their natural courses.
Now that we have some criteria, no matter how imperfect, from
separating benign frommalignant, and we now know the differentiation
of the constituent cells, we can analyze the morphologic characteristics
more speciﬁcally, with emphasis on site differences. First, the gross
characteristics.
GROSS FEATURES
GISTs, both benign and malignant, are almost always circumscribed
rather than inﬁltrative, although some of the largest malignant
tumors grow as a conﬂuence of multiple nodules. The smallest
tumors are conﬁned to the submucosa, muscularis propria, or both in
combination, while the large ones also protrude into the subserosa.
The smallest tumors are solid. The cut surfaces are pale and ﬁnely
granular with scattered dark vascular spots. Larger ones, especially those
that have ulcerated are likely to be cystic with central liquefaction and
hemorrhage. Someof the largest tumors, both benign andmalignant, have
huge central cysts with only thin rims of viable tumor.
SITE SPECIFICITY
GISTs arise predominantly in the stomach and small intestine.
Colonic GISTs are rare, whereas, rectal GISTs are more common.
A few appendiceal GISTs have been reported, but there are too few
for signiﬁcant data analysis. Hardly any GISTs arise in the esophagus,
yet the esophagus is themajor site for totally differentiated leiomyomas.
Speciﬁc GISTs, both benign and malignant, as well as mesenchymal
tumors that are not GISTs, generally arise in speciﬁc sites. Thus, the
stromal tumors are not the same in all areas of the gastrointestinal tract.
Furthermore, a particular type of tumor in one site may be
predictably benign, whereas a histologically similar, although not
necessarily identical, tumor arising in a second site may be predictably
malignant. This type of local variability has beenwell known and totally
accepted for mesenchymal tumors arising in extra-gastrointestinal sites.
For instance, we appreciate the fact that certain bone tumors arise
commonly in certain bones and rarely or never in other bones. We
know that rhabdomyosarcomas of the head and neck are likely to be of
the embryonal subtype, whereas those of the peripheral soft tissues
more commonly have the alveolar pattern. Similarly, the esophageal
mesenchyme seems capable of producing a cast of tumors different
from that produced by the mesenchyme in its immediately distal
neighbor, the stomach.
Actually, there is one stromal tumor that is common to all sites.
That is a small tumor located in the muscularis propria of any part of the
gut, often straddling the myenteric plexus, which sometimes seems to
blendwith the tumor cells [43]. These tiny tumors are often sclerotic and
periodically have calciﬁc foci. Most of the reported tumors have been in
the stomach, since that iswhere they aremost common. They are usually
found by abdominal surgeons who come across these tiny bumps during
procedures for other reasons, such a cancer resections. Because of their
location in the muscularis, they tend to look like subserosal nodules and
resemble nodules ofmetastatic cancer. As a result, they are often sent for
frozen section. For this reason, they have been known colloquially as
‘‘incidentalomas.’’ A recent publication referred them as ‘‘tumorlets,’’ a
remarkably creative designation [43].
The following is a collection of often little known and possibly
minimally important facts about GISTs and other mesenchymal
tumors in speciﬁc sites in the gut. There are data concerning relative
distribution, and likelihood of malignancy at each site.
Esophageal Stromal Tumors (ESTs)
In the esophagus, small, typical, differentiated leiomyomas
frequently arise in the two muscle layers, especially the muscularis
propria. Granular cell tumors occur here more than anywhere else.
There are too few esophageal GISTs for there to be any meaningful
conclusions about their morphologic characteristics and behavior.
The largest series, that from the AFIP, only has 17 cases [17].
The few reported tumors seem to be identical to those in the stomach.
In fact, some arose at the GE junction, so they may actually have been
primary in the proximal stomach and not the distal esophagus.
Gastric Stromal Tumors (GASTs)
Since GASTs are the most common GISTs, by far, there is a richer
literature about them than about stromal tumors elsewhere
[5,6,9,11,18,19,27,44,45]. About 1/5 of the GASTs are malignant.
The benign ones come in two varieties, spindle cell and epithelioid
cell. Because the stomach ﬂoats within the upper peritoneal cavity and
because of the size of the viscus itself, even benign stromal tumors can
grow to enormous sizes, especially if they arise on the greater curvature
and project into the peritoneal cavity or into the omentum.As a result, in
the stomach, large benign tumors are more common than they are
elsewhere. The benign spindle cell tumors often make spectacular
microscopic palisades, and the cells commonly have a single vacuole
that compresses the nucleus at one pole. Benign epithelioid cell tumors
often contain giant cells, some with single nuclei and many with
multiple nuclei, and these nuclei may be pleomorphic. In contrast,
malignant epithelioid cell tumors rarely contain pleomorphic cells
but are composed of small, tightly packed uniform cells. Malignant
GASTs sometimes have an unusual myxoid stroma. Furthermore,
although gastric stromal tumors are found mostly in the body of the
stomach, some types arise preferentially in the cardia and fundus, while
others are rarely found there. Thus, there is site speciﬁcity even within
this single viscus.MalignantGASTs are aggressive tumorswith a 5-year
survival of about 40%. The most common metastatic sites are the
peritoneal surfaces and liver, followed by the retroperitoneum and nodes
in about 15% of cases. The only syndrome that includes gastric stromal
tumors is Carney’s triad, which usually occurs in young females who
TABLE II. Modiﬁed Approach for Deﬁning Risk of Aggressive Behavior in
GISTs, Separating Stomach from Small Bowel (2007) [42]
Mitotic index
Tumor feature Risk of tumor progression
Size (cm) Stomach Small bowel
<5 per 50 HPF 2 Very low Very low
>2  5 Very low Low
>5  10 Low Moderate
>10 Moderate High
5 per 50 HPF 2 Very low Moderate
>2  5 Moderate High
>5  10 High High
>10 High High
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have multiple small malignant epithelioid cell tumors with a low
metastatic risk, functioning mainly extra-adrenal paragangliomas
that are also often multiple, and multiple pulmonary cartilaginous
tumors or chondromas [46]. The most common combination is gastric
and pulmonary tumors. Not every patient has all the three original parts
of the syndrome. In a 1999 publication, Carney added three more
components, non-functioning adrenal cortical tumors that occur in
about 15% and esophageal leiomyomas and duodenal stromal tumors
that occur in about 10% each [47].
The stomach is almost the exclusive gastrointestsinal site for glomus
tumors which can mimic the epithelioid GASTs, but which are com-
posed of smooth muscle cells which stain accordingly. The stomach is
also the most common site for a peculiar Schwannoma variant which is
also composed of spindle but which makes a lot of collagen, something
not found in stromal tumors, and it also tends to be surrounded by a cuff
of lymphocytes.
Duodenal Stromal Tumors (DUSTs)
There are only a few publications dealing speciﬁcally with DUSTs,
separate from other small bowel tumors [20,48]. Five to 10% of GISTs
arise in the duodenum, mostly in the second part where they are equally
split between benign and malignant. Tumors arising more distally are
mostly malignant. DUSTs tend to be on the medial wall and push into or
even invade the pancreas. Microscopically, they are almost all spindle
cell tumors. There are several patterns of growth, which help to dis-
tinguish benign frommalignant. Benign DUSTs often have an organoid
pattern superﬁcially in the submucosa, in which bundles of tumor cells
are separated by ﬁne ﬁbrous septa containing small vessels. Benign
tumors also commonly have rounded or elongated big lumps of colla-
gen, known as skeinoid ﬁbers, scattered among the spindle cells,
especially deep in the tumors. In contrast, malignant DUSTs usually
have neither an organoid pattern or skeinoid ﬁbers. Almost all
tumors larger than 4 cm across are malignant. The 5-year survival
for malignant DUSTs is about 2½ years. The usual sites of metastases
are liver in almost all cases, peritoneal surfaces, retroperitoneal soft
tissue, bone, and nodes in about 25% each. Peculiarly, in the duodenum
and the rest of the small bowel, predominantly epithelioid cell tumors
are almost all malignant, in contrast to the stomach where they are
mostly benign.
Small Intestinal Stromal Tumors (SISTs)
The small intestine is the second most common site for GISTs, so
the literature is substantial [7,8,21,49–51]. About 1/5 of all SISTs arise
in the jejunum and ileum. There have been a few reports of tumors
arising within Meckel’s diverticula, but most of these are probably
tumors that have become centrally necrotic and cystic and therefore
looked like diverticula. The ﬁndings of an organoid pattern and skeinoid
ﬁbers are as helpful in identifying benign tumors in the jejunoileum as
in the duodenum. From various published reports, it seems that about
40–50% of all SISTs are malignant, although the number varies from
study to study, and in many studies, the criteria for malignancy are not
even stated.
The 5-year survival for all malignant SISTs is about 25%.
Thus, most malignant SISTs are aggressive lesions. The usual sites
ofmetastases are the liver and peritoneal surfaces in about 70%, the lung
in only about 10% and the lymph nodes hardly ever.
There are two published studies in which speciﬁc morphologic
features were correlated with known metastases. The results are
comparable by univariate analysis with cellularity, mitotic count, size,
epithelioid cell morphology, and mucosal invasion all of which corre-
lated with metastases, but in the study that evaluated the parameters by
multivariate analysis, only cellularity and mitoses were independent,
signiﬁcant markers of metastasis.
Colonic Stromal Tumors (COSTs)
There is little data on stromal tumors of the abdominal colon, because
they are so uncommon [21,52]. Most of the published data lumps
colonic with anorectal tumor, but they are separate entities and have
to be analyzed separately. The largest published series only has 37 cases.
They are perhaps only half as common as those in the rectum. As best as
we can tell, stromal tumors of the abdominal colon are mostly malig-
nant, are histologically composed of spindle cells, but are nevertheless
histologically heterogeneous and behave aggressively. In fact, in the
largest series, nearly all tumors over 1 cm across with more than ﬁve
mitoses in 50 high power microscopic ﬁelds were fatal. In the only
studies comparing colonic with rectal sarcomas, the 5-year survival
for colonic tumors was close to 20%, while it was nearly 60% for
rectal tumors. A few GISTs have been found in the appendix, but there
are too few for meaningful data. The largest series only has four
cases [23].
Rectal Stromal Tumors (RESTs)
The rectum, and, to a lesser extent, the sigmoid colon, contain two
different mesenchymal neoplasms. One is a small nodular expansion of
themuscularismucosae, the leiomyomatous polyp. The second is a deep
intramural highly cellular spindle cell stromal tumorwhich superﬁcially
resembles the benign spindle cell lesion in the stomach, but which is
likely to be malignant [24,53–57]. RESTs tend to arise in the distal
rectum, so they may appear to involve the anus as well, and some of the
publications refer to the rectum and anus as being a single primary site.
Most of them are composed of long, large spindle cells. In contrast to
spindle cell tumors in other sites where the malignant tumors are
composed of small, more crowded cells; in the rectum even the malig-
nant ones have large cells. Histologically, the malignant RESTs are
often deceptively benign appearing. Possibly because of their location in
the muscularis propria which puts them deep in the pelvis, coupled
with the difﬁculty in removing them completely short of an abdominal-
perineal resection, these tumors tend to recur, occasionally several times
before they metastasize. Furthermore, they are often slow growing, so
recurrences may not appear until 5 or more years after resection, and
several recurrences may occur before metastases appear. This has led to
a problem analyzing survival, because too many reported cases of
supposedly benign tumors have not been followed long enough to
determine if they truly are benign. Ten years minimum follow-up
may be necessary before a deep intramural rectal tumor can be thought
of as benign, and in some cases even 10 years is not long enough. It is
conceivable that almost every deep intramural spindle cell stromal
tumor of the anorectum that involves the muscularis propria is malig-
nant, maybe not at ﬁrst, but subsequently after one or more recurrences.
Those tumors completely conﬁned to the submucosa seem to behave as
if they are benign, although some of them are histologically bizarre.
HOW TO DEALWITH GISTs IN THE MANAGED
CARE ENVIRONMENT?
Managed care stresses ﬁscal responsibility, often coupled with proﬁt
for the provider, at the same time not always emphasizing excellence in
quality. The following are the important GIST issues with which path-
ologists must deal, in order to accomplish efﬁcient, satisfactory diag-
nosis, recognizing economic constraints, yet without sacriﬁcing quality.
The Use of Needle Biopsies
These days, many GISTs are ﬁrst encountered by pathologists as
needle biopsies of large intra-abdominal masses. Because of current
drug therapy for malignant GISTs that require not just the GIST
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diagnosis but demonstration of c-kit positivity, pathologists dealing with
these small samples are faced with several potential problems.
(1) First, we have to determine if the biopsy came from a GISTor some
other tumor type. We have seen such biopsies that we cannot
classify with conﬁdence.
(2) Sometimes it may not be possible, based solely on imaging
studies, to determine if a huge abdominal tumor has arisen in the
gut or in some other site such as the omentum, mesentery, or
retroperitoneum.
(3) Furthermore, it may not be possible to tell in what part of the gut
a huge tumor arose. Right now, we do not know how important
site of origin is in determining the efﬁcacy of the new therapies.
(4) Once we determine that the tumor is a GIST, then we need to
determine if it is malignant. Most malignant GISTs are easy to
diagnose as malignant based on cellularity and mitoses. There
are large benign tumors that may be needled, and it may be
difﬁcult to determine with conﬁdence if that tumor is malignant,
based upon the small sample size. Inmany sarcomas, there are areas
that look benign. Ancillary ﬁndings, including mucosal invasion
will not be present in needle biopsies.
(5) If the tumor is a GIST and it is malignant, how should a negative
c-kit stain be interpreted? A small set of GISTs are kit negative.
In addition, we have seen GISTs with variable c-kit staining from
one area to another, and the needle may only capture a negative
focus.
(6) Furthermore, how should we interpret a tumor that does not
look like a GIST, but which is c-kit positive? As we examine
more and more mesenchymal tumors with better antibodies, we
may ﬁnd that there are non-GISTs that are c-kit positive. About a
quarter of angiosarcomas are kit positive as are most mesenteric
ﬁbromatoses, although neither of these look anything like a GIST.
Melanomas which can resemble malignant GISTs are also often
positive.
At the moment, these issues have not been resolved, but they will
have to be resolved, if needle biopsies are to be considered as diagnos-
tically deﬁnitive and if they direct therapy.
The Use of Frozen Section and Gross
Intra-Operative Consultation
Many GISTs are discovered incidentally during laparotomies for
other reasons, so they are surprises to the surgeon, who may want to
know immediately what type of tumor it is. Since GISTs are expansile
intramural tumors with variable extramural components, the gross
differential diagnosis is GIST, metastatic tumor, and much less likely,
lymphoma. Primary GI carcinomas do not have such gross appearances.
If the size guidelines are used to help determine if a tumor is malignant,
the careful size measurement should be undertaken. Perhaps measuring
it three or four times by different pathologists may help to alleviate
measurement inconsistency.
On a frozen section, often the best a pathologist can often do is to
identify the tumor asmesenchymal, but even that canbedifﬁcult, especially
with the epithelioid cell gastric tumors that mimic carcinoma on frozen
section. The determination of whether it is benign ormalignant usually can
only be made later when the permanent sections are available. Even in
provenmalignant tumors, themitotic rate canbevery low, nomore thanone
or two mitotic ﬁgures in 50 high power microscopic ﬁelds, an impossible
determination tomakeon frozen section. Furthermore, almost every benign
tumor looks highly cellular on frozen sections that are usuallymuch thicker
than permanent sections. In rare tumors the cellularity and numbers of
mitotic ﬁgures are so great that the diagnosis ofmalignancy is easy, even on
frozen section. If a tumor is malignant, then, as mentioned above, size
correlateswithmetastatic risk. If the surgeonasksus to evaluate themargins
of resection, that usually can be done grossly, since these are not very
inﬁltrative tumors.
The Best Use of the Pathologist’s Time
Careful evaluation of the H&E stained sections is most
important, looking for the features described above. Mitotic counts are
not reproducible from one pathologist to another, but if a pathologist
adheres to the current diagnostic and staging guidelines such as are part of
the ﬁrst ever AJCC GIST staging in 2010, then counting mitoses is
necessary. If the tumor has mitoses that are easily found when
scanning several high power ﬁelds, that is good, although not
unequivocal, evidence ofmalignancy. There are no rules based on proven
facts as to how many blocks of a tumors are necessary to evaluate, but in
my undocumented experience, no more than 4–5 blocks, even from the
largest tumors, will probably be sufﬁcient to tell if it is malignant. If the
tumor is ulcerated, a couple of blocks from the ulcer edges in order to
detect mucosal invasion are suggested.
The Need for Special Studies
This is dealt with in Chapter 1. Actually there is not a single immuno
stain or combination of stains that will improve diagnosis over
simple H&E, but staining for c-kit protein seems to be the standard
for diagnosis. Therefore, if a bowel wall tumor is suspected as being
a GIST, then the only stain that needs to be done is the c-kit. If that
is negative, then other antibodies can be used. A c-kit negative tumor is
unlikely to be a GIST, since few GISTs are kit negative, but remember
that a few of them are.
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